This study is comparing two treatments for recurrent glioblastoma (a type of aggressive brain cancer that has returned): Cerebraca Wafer plus temozolomide versus temozolomide alone. Cerebraca Wafer is an implant used during surgery, and temozolomide is a standard chemotherapy drug. The study aims to see if adding Cerebraca Wafer improves how long people live. You might be able to join if you are 18 or older, have glioblastoma that has returned for the first or second time after initial treatment, and have completed prior surgery, temozolomide, and radiation. The study is looking for 175 participants. The current recruitment status is unclear.

Study design

This is a multi-center, randomized, open-label study, meaning participants are randomly assigned to a treatment group, and both you and your doctors will know which treatment you are receiving. It plans to enroll 175 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main goal is to measure how long participants live, with this being assessed at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.